TY - JOUR
T1 - The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease
AU - Chen, Shengdi
AU - Chan, Piu
AU - Sun, Shenggang
AU - Chen, Haibo
AU - Zhang, Baorong
AU - Le, Weidong
AU - Liu, Chunfeng
AU - Peng, Guoguang
AU - Tang, Beisha
AU - Wang, Lijuan
AU - Cheng, Yan
AU - Shao, Ming
AU - Liu, Zhenguo
AU - Wang, Zhenfu
AU - Chen, Xiaochun
AU - Wang, Mingwei
AU - Wan, Xinhua
AU - Shang, Huifang
AU - Liu, Yiming
AU - Xu, Pingyi
AU - Wang, Jian
AU - Feng, Tao
AU - Chen, Xianwen
AU - Hu, Xingyue
AU - Xie, Anmu
AU - Xiao, Qin
N1 - Funding Information:
This work was supported by the National Key Basic Research Program of China [grant numbers G1999054008, 2006cb500706, 2011CB504104], the National Natural Science Foundation of China [grant number 81430022], and the Shanghai Science and Technology Fund [grant number 10411954500].
Publisher Copyright:
© 2016 The Author(s).
PY - 2016/6/30
Y1 - 2016/6/30
N2 - Background: Parkinson's disease (PD) is a chronic, progressive and debilitating disease, which affects over 2.5 million people in China. PD is characterized clinically by resting tremor, muscular rigidity, bradykinesia and postural instability. As the disease progresses, additional complications can arise such as non-motor and neurobehavioral symptoms. Pharmacological treatment and surgical intervention for PD have been implemented in China. Until 10 years ago, there was lack of standardization for the management of PD in different regions and among different physicians, leading to different treatment levels in different regions and different physicians. Since then, the Chinese Parkinson's Disease and Movement Disorder Society have published three versions of guidelines for the management of PD in China, in 2006, 2009 and 2014, respectively. Correspondingly, the overall level of treatment for PD in China improved. Objectives: To update the treatment guidelines based on current foreign and domestic practice guidelines and clinical evidence, and to improve the treatment options available to physicians in the management of PD. Summary: A variety of treatment recommendations in the treatment guidelines have been proposed, including physical activity and disease-modifying medication, which should be initiated at the early-stage of the disease. The principles of dosage titration should be followed to avoid acute adverse reactions to the drugs, to achieve a satisfactory clinical effect with a low dose and to reduce the incidence of long-term motor complications. Moreover, different treatment strategies should be considered at different stages of the disease. Importantly, treatment guidelines and personalized treatments should be valued equally. A set of treatment recommendations has been developed to assist physicians to improve and optimize clinical outcomes for patients with PD in China.
AB - Background: Parkinson's disease (PD) is a chronic, progressive and debilitating disease, which affects over 2.5 million people in China. PD is characterized clinically by resting tremor, muscular rigidity, bradykinesia and postural instability. As the disease progresses, additional complications can arise such as non-motor and neurobehavioral symptoms. Pharmacological treatment and surgical intervention for PD have been implemented in China. Until 10 years ago, there was lack of standardization for the management of PD in different regions and among different physicians, leading to different treatment levels in different regions and different physicians. Since then, the Chinese Parkinson's Disease and Movement Disorder Society have published three versions of guidelines for the management of PD in China, in 2006, 2009 and 2014, respectively. Correspondingly, the overall level of treatment for PD in China improved. Objectives: To update the treatment guidelines based on current foreign and domestic practice guidelines and clinical evidence, and to improve the treatment options available to physicians in the management of PD. Summary: A variety of treatment recommendations in the treatment guidelines have been proposed, including physical activity and disease-modifying medication, which should be initiated at the early-stage of the disease. The principles of dosage titration should be followed to avoid acute adverse reactions to the drugs, to achieve a satisfactory clinical effect with a low dose and to reduce the incidence of long-term motor complications. Moreover, different treatment strategies should be considered at different stages of the disease. Importantly, treatment guidelines and personalized treatments should be valued equally. A set of treatment recommendations has been developed to assist physicians to improve and optimize clinical outcomes for patients with PD in China.
KW - Parkinson's disease
KW - Treatment guideline, optimal therapeutic options, China
UR - http://www.scopus.com/inward/record.url?scp=84976416035&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976416035&partnerID=8YFLogxK
U2 - 10.1186/s40035-016-0059-z
DO - 10.1186/s40035-016-0059-z
M3 - Review article
AN - SCOPUS:84976416035
SN - 2047-9158
VL - 5
JO - Translational Neurodegeneration
JF - Translational Neurodegeneration
IS - 1
M1 - 12
ER -